We previously found that mRNA levels of OVOL2 decreased at a late stage of human breast cancer progression.[20] To further elucidate the impact of OVOL2 on breast cancer carcinogenicity, we analyzed OVOL2 expression across different molecular subtypes using data from UALCAN and Oncomine databases. This evidence concerns the gene OVOL2 and breast carcinoma.